Stockreport

Disc Medicine: Achieving Functional Endpoint More Important [Seeking Alpha]

Disc Medicine, Inc.  (IRON) 
PDF Play 8min Summary Disc Medicine's lead molecule, bitopertin, failed to meet key functional endpoints in phase 2 trials for Erythropoietic Porphyrias, causing a si [Read more]